ALXO: Lead immuno-oncology and ADC programs advance toward pivotal trials with strong biomarker focus
Two lead programs, evorpacept and ALX2004, are advancing toward pivotal studies, with key data readouts expected in the next 12—24 months. Evorpacept's biomarker-driven approach and ALX2004's novel epitope offer strong differentiation, while a solid cash position supports continued progress.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.